



September 6, 2016

Dicerna to Present at September Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the following investor conferences in September.

- 1 Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016 at 2:35-3:00 p.m. ET at the Lotte New York Palace Hotel in New York City.
- 1 Leerink Partners Rare Disease and Immuno-Oncology Roundtable Series on Wednesday, September 28, 2016 at 10:35-11:00 a.m. ET at the Lotte New York Palace Hotel in New York City.

A live webcast of each presentation can be accessed on the Investors & Media section of the Dicerna website at www.dicerna.com. An archived replay of the webcasts will be available on the Company's website after each conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is an RNA interference-based biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver, for other therapeutic areas in which the liver plays a key role, and for cancers that are genetically defined. The Company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In many cases, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize these novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20160906006382/en/>

Investors:

Rx Communications Group
Melody Carey, 917-322-2571
mcarey@rxir.com

or

Media:

SmithSolve
Alex Van Rees, 973-442-1555, ext. 111
alex.vanrees@smithsolve.com

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media